.jpg "Alan Wookey photo")
VP Companion Diagnostics & Oncology
Q2 Solutions
Naples, Florida
Alan Wookey. VP Companion Diagnostics & Oncology. Q2 Solutions.
Alan leads the Business Development & Scientific strategy for Companion Diagnostics and is Oncology Subject Matter Expert for biomarkers and Precision Medicine.
Alan has experience of more than 20 years in senior scientific leadership positions within the Pharmaceutical and Laboratory sectors and was the Director and Head of Oncology Biomarker Group at AstraZeneca (AZ).
He built a Clinical Biomarkers Group from scratch to service biomarker needs for the AZ Oncology portfolio and was part of a broad functional team that brought the EGFR mutation test to the market following successful IPASS study for Iressa.
Alan planned and set-up a laboratory in China to deliver biomarker results used for global submissions and received a Clinical Excellence award at AstraZeneca for this work.
More recently, Alan was Associate Vice President , LabCorp Clinical Trials (now Covance) and led scientific, regulatory and commercial components towards the launch of its own proprietary Companion Diagnostics including the PDL1 program from Merck into LabCorp and set up commercial agreement to ensure service supply of assay following FDA approval.
Disclosure information not submitted.
Wednesday, October 19, 2022
9:30 AM – 10:00 AM ET